Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$646M |
| 2 |
Tesla
TSLA
|
+$572M |
| 3 |
Broadcom
AVGO
|
+$521M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$478M |
| 5 |
lululemon athletica
LULU
|
+$400M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.14B |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$861M |
| 3 |
Palantir
PLTR
|
+$730M |
| 4 |
iShares Bitcoin Trust
IBIT
|
+$576M |
| 5 |
NVIDIA
NVDA
|
+$443M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 94.35% |
| 2 | Technology | 1.74% |
| 3 | Consumer Discretionary | 0.9% |
| 4 | Financials | 0.71% |
| 5 | Communication Services | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DDL
11826
Dingdong
DDL
$496M
| $56K | ﹤0.01% |
27,029
+1,114
| +4% | +$2.41K |
|
11827
Milestone Scientific
MLSS
$44.5M
| $55.5K | ﹤0.01% |
122,139
-37,376
| -23% | -$21.9K |
|
11828
Marchex
MCHX
$81.6M
| $55.4K | ﹤0.01% |
30,924
-52,371
| -63% | -$104K |
|
|
NAKA
11829
CALL
Nakamoto Inc
NAKA
$133M
| $55.2K | ﹤0.01% |
+1,290
| New | +$409K |
|
|
NBP
11830
CALL
NovaBridge Biosciences American Depositary Shares
NBP
$213M
| $55.2K | ﹤0.01% |
+14,600
| New | +$49.6K |
|
|
TRVG
11831
trivago
TRVG
$423M
| $55.1K | ﹤0.01% |
16,525
-83,871
| -84% | -$297K |
|
11832
Advantage Solutions
ADV
$442M
| $55.1K | ﹤0.01% |
1,440
-5,144
| -78% | -$214K |
|
11833
CALL
National CineMedia
NCMI
$245M
| $55K | ﹤0.01% |
+12,200
| New | +$56.9K |
|
11834
Celularity
CELU
$45.7M
| $54.7K | ﹤0.01% |
+26,410
| New | +$73.9K |
|
11835
E.W. Scripps
SSP
$302M
| $54.7K | ﹤0.01% |
22,223
-80,993
| -78% | -$249K |
|
|
MREO
11836
PUT
Mereo BioPharma
MREO
$40.3M
| $54.6K | ﹤0.01% |
26,500
-85,100
| -76% | -$157K |
|
|
JCTC
11837
Jewett-Cameron Trading
JCTC
$10.4M
| $54.4K | ﹤0.01% |
+15,917
| New | +$57.7K |
|
11838
PUT
eHealth
EHTH
$38.4M
| $54.3K | ﹤0.01% |
+12,600
| New | +$48.4K |
|
11839
PUT
Flux Power
FLUX
$13.5M
| $53.9K | ﹤0.01% |
+14,400
| New | +$29.2K |
|
11840
ProQR Therapeutics
PRQR
$323M
| $53.8K | ﹤0.01% |
+25,245
| New | +$55.2K |
|
11841
PUT
Inovio Pharmaceuticals
INO
$133M
| $53.4K | ﹤0.01% |
22,800
+9,100
| +66% | +$17.4K |
|
|
STLN
11842
PUT
Starling Oncology
STLN
$629M
| $53K | ﹤0.01% |
+15,200
| New | +$52.1K |
|
|
LNAI
11843
CALL
Lunai Bioworks
LNAI
$10.7M
| $53K | ﹤0.01% |
4,663
+3,468
| +290% | +$66.9K |
|
|
NINE
11844
DELISTED
Nine Energy Service
NINE
| $52.6K | ﹤0.01% |
83,279
-78,013
| -48% | -$55.6K |
|
11845
CALL
Protalix BioTherapeutics
PLX
$205M
| $52.4K | ﹤0.01% |
23,600
-144,300
| -86% | -$235K |
|
11846
CALL
Nuvation Bio
NUVB
$2.34B
| $52.2K | ﹤0.01% |
14,100
-1,198,500
| -99% | -$3.27M |
|
|
CERO
11847
DELISTED
CERo Therapeutics
CERO
| $52.1K | ﹤0.01% |
+10,244
| New | +$75.4K |
|
11848
NetSol Technologies
NTWK
$49M
| $52.1K | ﹤0.01% |
10,959
-2,624
| -19% | -$10.9K |
|
11849
Data I/O
DAIO
$30.5M
| $51.5K | ﹤0.01% |
15,428
-7,280
| -32% | -$23.6K |
|
11850
PUT
VistaGen Therapeutics
VTGN
$11.2M
| $51.5K | ﹤0.01% |
+14,500
| New | +$43.3K |
|
Similar funds
Jeff Yass's Q3 2025 Portfolio in Review
As of Q3 2025, Jeff Yass held 14,336 positions worth $875B, up 22% from $720B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Jeff Yass's Q3 2025 filing shows 1,794 new, 5,240 increased, 5,148 reduced and 2,105 closed positions. Its largest new stake was BitMine Immersion Technologies: 7,689,603 shares worth $399M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $1.14B.
By sector, the portfolio is most concentrated in Miscellaneous at 94% of assets, up from 94% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jeff Yass's largest Q3 2025 buy was BitMine Immersion Technologies: 7,689,603 shares worth $399M.
- Jeff Yass added most to Meta Platforms (Facebook) in Q3 2025, an estimated $646M increase.
- Jeff Yass's biggest Q3 2025 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.14B.
- Jeff Yass fully exited iShares Core MSCI Total International Stock ETF in Q3 2025, selling an estimated $123M.
- Jeff Yass's ten largest holdings make up 24% of its $875B portfolio in Q3 2025.
- Jeff Yass opened 1,794 new positions and closed 2,105 in Q3 2025.
- Jeff Yass's portfolio value rose 22% quarter-over-quarter to $875B.
Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.